Kornimate/medical-research-clean huggingface dataset:
exercise study on cardiac function in patients with diabetes mellitus type 2 and diastolic dysfunction

Conditions: Diabetes Type 2

Summary: the aim of the study is to compare the effects of aerobic interval training and the idf recommendations on physical activity on cardiac function and cv risk factors in patients with diabetes. the hypothesis is that ait more than mct, will improve myocardial dysfunction in patients with subclinical lv disease, improve both endothelial function and vo2max and thus reducing cv risk factors and cv disease. hba1c will be more stable. the aims of this study are to address the exercise prescription recommendations for patients with (t2dm) who have subclinical heart disease. the prescription recommendations will be assessed by randomising t2dm patients with subclinical heart disease to one of the following 2 groups for 3 months followed by a 9 month home-based program: moderate intensity exercise group (me). home exercise equivalent to the present exercise recommendations of the international diabetes federation. aerobic interval training (ait). exercise equivalent to the current guidelines achieved through high-intensity interval training.

the investigators primary hypotheses are that in patients with type 2 diabetes and subclinical heart disease: moderate intensity exercise will: not significantly improve myocardial function compared to controls, despite significant improvement (compared to controls) in: glycaemic control (hba1c) cardiorespiratory fitness (vo2max) body composition (dxa) aerobic interval training group will: significantly improve myocardial function compared to controls, significantly improve (compared to moderate intensity exercise group): glycaemic control (hba1c) cardiorespiratory fitness (vo2max) body composition (dxa)

Eligibility criteria:
inclusion criteria: * patients 20-60 years with diagnose diabetes mellitus type 2 (without insulin) for less than 10 years and with diastolic dysfunction (e'\<8), will be included. exclusion criteria: * overt cv disease * history of cad * moderate to severe valvular disease (ai mi 3-4, as peak gradient \> 15 mmhg=2m/s) * atrial fibrillation or other severe arrhythmia * congenital heart disease * untreated hypertension \>140/90 * lvh * retinopathy * neuropathy * micro or macroalbuminuria * ef \< 40% * bmi \>35 * ischemia at exercise echocardiography * disease or disability making training difficult.

Keywords: diabetes type 2 exercise tissue doppler velocity
odiparcil for the prevention of venous thromboembolism

Conditions: Deep Vein Thrombosis; Fibrillation, Atrial; Venous Thromboembolism; Pulmonary Embolism

Summary: odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.


Eligibility criteria:
inclusion criteria: * women must be unable to have children. * will have a total knee replacement. exclusion criteria: * allergic to any x-ray dye. * allergies or reactions to warfarin or coumadin. * previous vte (venous thromboembolism) or deep vein thrombosis (dvt). * on anticoagulation therapy. * renal impairment. * participated in any clinical trial in the past 30 days.

Keywords: deep vein thrombosis total knee replacement pe venous thromboembolism dvt pulmonary embolism vte
impact of medication therapy management intervention on treatment outcomes and medication adherence among adult patients comorbid with diabetes mellitus and hypertension at outpatient clinics

Conditions: Diabetes Mellitus; Hypertension

Summary: the goal of this interventional study was to assess the impact of medication therapy management on treatment outcomes and medication adherence among adult patients comorbid with diabetes mellitus and hypertension at outpatient clinics in southwest ethiopia. the patients attending hospitals assigned to interventional group received medication therapy management services in addition to usual care.

this study aimed to assess the impact of medication therapy management intervention on treatment outcomes and medication adherence among patients comorbid with diabetes mellitus and hypertension at outpatient clinics in southwest ethiopia. a cluster randomized controlled trial was conducted at outpatient clinics of public hospitals in southwest ethiopia from march to december, 2022. hospitals were randomly assigned to either the interventional or the control group. the patients attending hospitals assigned to interventional group received medication therapy management services in addition to usual care and those attended hospital assigned to control group received the usual care only. a systematic random sampling technique was used to select the study participants from each hospital. the differences in proportion between the groups was determined using the pearson chi-square. the independent sample t-test was be done to compare means between groups and paired t-test was used to compare means in between intervention and controlled group. the p-value of \< 0.05 was used as a cut-off point to declare statistical significance.

Eligibility criteria:
inclusion criteria: * age is greater than or equal to 18 years * diagnosed with both diabetes mellitus and hypertension exclusion criteria: * unwillingness to participate * mentally disabled * lost to follow-up * change follow up site * pregnant women

Keywords: treatment outcomes medication adherence diabetes mellitus and hypertension southwest ethiopia
a study to evaluate the efficacy, safety and tolerability of miv-711 in osteoarthritis patients

Conditions: Osteoarthritis, Knee

Summary: this is a multicentre, randomised, placebo-controlled, double-blind, three-arm parallel, phase iia study to evaluate the efficacy, safety and tolerability of miv-711 in patients with knee osteoarthritis (oa).


Eligibility criteria:
inclusion criteria: * current average knee pain, defined as pain in either knee, within 1 week before visit 1, for which the patient gives a severity score of ≥4, \<10 on a 0-10 nrs (numeric rating scale). * inclusive of 40-80 years old. * diagnosis of primary knee osteoarthritis exclusion criteria: * the presence of any inflammatory arthritis * any generalized pain condition that may interfere with the evaluation of the target knee pain (e.g., fibromyalgia) as judged by the investigator. * any clinically severe or significant uncontrolled concurrent illness, which, in the opinion of the investigator, would impair ability to give informed consent or take part in or complete this clinical study. * known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients.
hmpl-453 in advanced malignant mesothelioma

Conditions: Advanced Malignant Mesothelioma

Summary: this is a phase ii, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of hmpl-453 in patient with advanced malignant mesothelioma

histologically confirmed patients with advanced malignant mesothelioma that who was failure of the first -line systemic therapy

Eligibility criteria:
inclusion criteria: * 1.signed written informed consent; * 2.18 years of age or older; * 3.histologically diagnosed malignant mesothelioma (including pleura, peritoneum, pericardium, and testicular tendon sheath origin, cell type epithelioid, sarcoma-like, or mixed type), and cannot be cured radically; * 4.received one to three regimen of prior systemic therapy and then experienced documented radiographic progression or intolerable toxicity; * 5.patients agreed to provide tumor tissue for fgf/fgfr testing; * 6.measurable disease by recist version 1.1 criteria; * 7.ecog performance status ≤ 2.; exclusion criteria: * 1.previous treatment with any fgfr inhibitor; * 2.received systemic anti-cancer therapy within 3 weeks of the first dose of hmpl-453; * 3.major surgery within 4 weeks of the first dose of hmpl-453; * 4.use of a strong inducer or inhibitor of cytochrome p450 3a4 (cyp3a4) within 1 week of the first dose of hmpl-453; * 5.inadequate conditions as indicated by the following laboratory values: * absolute neutrophil count (anc)\<1.5 x 109/l * hemoglobin \< 80 g/l * platelet count \<80 x 109/l * 6.any of the following conditions of liver and kidney insufficiency: * total bilirubin \> 1.5 x uln * ast and alt \> 2.5 x uln (\> 5 x uln for patients with liver metastases) * creatinine clearance of \< 50 ml/min as estimated by the cockcroft-gault equation * 7.international normalized ratio (inr) \>1.5 or activated partial thromboplastin time (aptt) \>1.5 x uln; * 8.clinical significant liver disease; * 9.known human immunodeficiency virus (hiv) infection * 10.previous history of retinal detachment; * 11.unable to swallow the study drug.
classic and modified rapid sequence induction for prevention of gastric content regurgitation

Conditions: Rapid Sequence Induction

Summary: induction of anesthesia induces a loss of protective upper airway reflexes and is associated with gastric content regurgitation. emergency surgery bears a higher risk of gastric content regurgitation because of full stomach, delayed gastric emptying, intestinal obstruction, stroke or other factors. rapid sequence induction (rsi) of anesthesia was recommended to minimize the risk of regurgitation and aspiration. classic rsi scheme mainly includes the use of short-acting sedatives and muscle relaxant, together with a manual pressure to the cricoid cartilage (sellick maneuver) which aims at compressing the esophagus to avoid regurgitation. though widely recommended, the scheme has been controversial for years. our department modified the scheme and put it into use in day shift emergency surgery since march 1, 2018. this retrospective analysis is aimed at comparing the effect of classic and modified rapid sequence induction in prevention of gastric content regurgitation in emergency surgery under general anesthesia.


Eligibility criteria:
inclusion criteria: * patients receive emergency surgery under general anesthesia march 1, 2015 to february 29, 2020 * eighteen years or older exclusion criteria: * trachea intubation status on admission * tracheotomy * bronchoscope surgery * general anesthesia with laryngeal mask * awake intubation
surgical resection enhances survival in gastric-type endocervical adenocarcinoma: a seer-based study

Conditions: Gastric-type Endocervical Adenocarcinoma

Summary: this retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (gas), using data from the seer database (2000-2021). propensity score matching and multivariable cox regression were used to compare overall survival (os) and tumor-specific survival (tss) between patients who underwent surgery and those who did not. the study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.

the study utilized de-identified data from the seer program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. the primary endpoints were overall survival and tumor-specific survival. statistical analyses included multivariable cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (iptw). subgroup analyses were performed based on figo stage and tumor size (\>4 cm). a total of 308 eligible cases were included. no patient interaction or clinical intervention occurred.

Eligibility criteria:
inclusion criteria: histologically confirmed gastric-type endocervical adenocarcinoma cervix as the first primary site diagnosis between 2000 and 2021 exclusion criteria: incomplete survival or treatment data diagnosis not confirmed microscopically
a single blinded study on the effect of saccharomyces boulardii cncm i-745 on growth and development in preterm infants

Conditions: Infant, Premature, Diseases

Summary: immature gastrointestinal functions increase the risk of poor growth as well as nosocomial infections and necrotizing enterocolitis (nec) in the preterm infant. the effects of probiotics on growth and development in premature infants have been investigated poorly. saccharomyces boulardii cncm i-745 (s. boulardii) is a non-pathogenic probiotic yeast. prophylactic supplementation of s. boulardii at a dose of 50 mg/kg twice a day appeared to bring preterm infants weight gain closer to that of intra-uterine growth rate, reduce feeding intolerance, and had no adverse effects.

the objective of this study is to evaluate if feeding supplemented with s. boulardii can improve growth and clinical outcomes in preterm and low birth weight infants. a prospective, randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g. the study group received s. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group. the primary outcomes were short term growth parameters including weight gain, linear growth, head and chest circumference, and secondary outcomes were clinical outcomes, feeding intolerance and complications. a total of 125 infants were enrolled in the study, 63 in the treatment and 62 in the control group. s. boulardii was administered for the first time at 2.63 days after birth (1 day to 6 days, 46 within 3 days, only 5 between 4 and 6 days).

Eligibility criteria:
inclusion criteria: * the inclusion criteria were hospital born infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g. exclusion criteria: * exclusion criteria were severe neonatal pathology such as birth complications, gi malformations, chromosomal abnormalities, known immunodeficiency, hydrops foetalis, a central venous catheter and the use of antifungal drugs or probiotics.
screening for chronic liver diseases in general population

Conditions: Fibrosis, Liver

Summary: improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.

the prevalence of chronic liver diseases continues to increase on the one hand by the increase in non-alcoholic fatty liver disease (nafld) which affects 25% of the general population as well as the increased incidence of hepatocellular carcinoma in recent years. screening for liver fibrosis in the general population represents a major public health issue. the fib-4 score is obtained by a blood test. this score combines age, measurement of alt/asat (alanine aminotransferase / aspartate-aminotransferase) and platelet count. this score is sensitive for detecting advanced fibrosis liver and allows 71% of patients to avoid a liver biopsy. transient elastometry (fibroscan®) is another very effective non-invasive assessment in the diagnosis of chronic liver diseases and hepatic fibrosis. it has already been demonstrated by several studies that combining several non-invasive fibrosis tests allows to improve the precision of the result. the investigators hypothesize that offering an additional assessment by fibroscan for patients screened by a blood test (fib-4 score) as possibly having advanced liver fibrosis (score \>1.3) will raise awareness among professional practitioners and the general population with chronic liver diseases and refine screening for chronic liver diseases.

Eligibility criteria:
inclusion criteria: * age ≥ 40 years * without known liver pathologies * having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the audit questionnaire, the presence of metabolic syndrome, diabetes or a risk factor for viral hepatitis b, d or c. exclusion criteria: * fibroscan already performed in the last 12 months * failure to collect express oral consent * patient not affiliated with or not benefiting from a national health insurance scheme * patient protected by law * patient under guardianship or curatorship * patient deprived of liberty * pregnant or breastfeeding woman

Keywords: non-alcoholic fatty liver disease (nafld) hepatocellular carcinoma (hcc) chronic liver diseases linkage to care fibrosis research non-invasive diagnosis fib-4 fibroscan
safety and efficacy of niclosamide in patients with covid-19 with gastrointestinal infection

Conditions: Covid19

Summary: this is a 2-part, 2-arm, phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with covid-19 with gastrointestinal infection.


Eligibility criteria:
inclusion criteria: 1. part 1 only, patients with a primary diagnosis of covid-19, with or without pneumonia, who agree to be monitored daily for at least 7 days after randomization and who accept continuing to be assessed for the study procedures. 2. part 2 only, patients with a primary diagnosis of covid-19, with or without pneumonia. exclusion criteria: 1. at the time of randomization, patients who require intensive care unit (icu) admission or patients with severe respiratory insufficiency who require mechanical ventilation or with rapid worsening of respiratory function leading to expectation for mechanical ventilation or icu admission. 2. evidence of rapid clinical deterioration or existence of any life-threatening co-morbidity or any other medical condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion. 3. patients who, at the time of enrollment, are not in a clinical condition compatible with the oral administration of the study drug.

Keywords: sars-cov-2 covid covid19 diarrhea covid19 gi infection
enhancing innate anti-viral resistance through a community-based intervention - generation xchange

Conditions: Virus Infection, RNA

Summary: this randomized controlled trial will test whether a recently developed community-based intergenerational mentoring program known as generation xchange (genx) can enhance antiviral resistance in older african-american women and men in a low-ses urban community. additional studies will identify the biological processes that promote resistance to respiratory virus infections and viral disease in older african-american women and men.

this randomized controlled intervention trial (planned n=160) will test whether participation in the generation xchange (genx) intergenerational mentoring program can reduces vulnerability to respiratory virus infections (covid, influenzas, colds), increase antiviral immune activity (type i interferon responses), and reduce inflammatory immune activity in older african-american women and men living in a socioeconomically disadvantaged urban community. blood samples will also be collected to determine which biological factors are most important in protecting older african-americans from respiratory virus infection, and which of those factors is affected by the genx intervention.

Eligibility criteria:
inclusion criteria: * participating in the genx intergenerational mentoring program * all genx mentors \> 50 years of age are eligible to participate in this research * genx program participation requires: * reside in neighborhood of genx schools (south-central los angeles) * pass basic literacy and cognitive function tests exclusion criteria: * any health condition that would put participant at risk by enrollment/participation
prospective exploratory study on rtms for migraine under the guidance of meg

Conditions: Migraine Disorders, Brain; rTMS Stimulation

Summary: using magnetoencephalography to locate and regulate targets in migraine patients, repeating transcranial magnetic stimulation to physically regulate targets, and evaluating the safety and effectiveness of this treatment method through headache related scales. using whole genome data and scale scores for correlation analysis, and conducting randomized controls with traditional drugs to explore new approaches for migraine.

migraine patients who meet the inclusion criteria will be randomly divided into two groups: the meg+rtms treatment group and the sibelium treatment group. evaluate the clinical efficacy (frequency of attacks (times/month), severity (visual analog scale), duration (d), analgesic drug use rate, and related scale scores) of the meg+rtms treatment group and the sibelium treatment group, respectively. evaluate its efficacy based on follow-up results and analyze the correlation between different genotypes and efficacy.

Eligibility criteria:
inclusion criteria: * complies with specific disease diagnosis: a. headaches that meet the criteria of b and c (headaches that meet the characteristics of tension headaches or migraines) should occur at least 15 days per month and last for at least 3 months; b. headaches that meet the criteria of 1.1 migraine without aura diagnosis b-d or 1.2 migraine with aura b and c occurring at least 5 times; c. headache meets any of the following criteria and occurs for more than 8 days per month, lasting for more than 3 months: ①1.1 c and d of migraine without aura②1.2 b and c of migraine with aura③ the migraine attack perceived by the patient can be relieved by taking triptan or ergot, which cannot be better explained by other diagnoses in ichd-3. * must be able to swallow tablets * signed and dated informed consent form promise to comply with research procedures and cooperate in implementing the entire research process exclusion criteria: * age under 15 years old; accompanied by optic disc edema, focal symptoms and signs of the nervous system (except for typical visual and sensory precursors) or cognitive impairment; sudden and rapidly peaking severe headaches (thunderous headaches) * accompanied by fever; new onset headaches in adults, especially after the age of 50; headaches in patients with high coagulation risk * new headache in patients with tumor or aids history; headaches related to changes in body position; * history of epileptic seizures

Keywords: migraine meg rtms rct
developing advanced mri methods for detecting the impact of nutrients on infant brain development

Conditions: Infant Development

Summary: the purpose is to study the effect of infant nutrition on brain development, as measured using magnetic resonance (mr) techniques. the investigators will collect detailed information about the diet of each of the infants, and seek to correlate this information with multiple mr measurements, including structural imaging, diffusion imaging, and functional connectivity. the mr scans will be performed at birth and 3 months of age. dietary information collected will include detailed food diaries describing the feeding habits of the infants, and food frequency questionnaires to characterize the diet of the mother.

the purpose is to study the effect of infant nutrition on brain development, as measured using magnetic resonance (mr) techniques. the investigators will collect detailed information about the diet of each of the infants, and seek to correlate this information with multiple mr measurements, including structural imaging, diffusion imaging, and functional connectivity. the mr scans will be performed at birth and 3 months of age. dietary information collected will include detailed food diaries describing the feeding habits of the infants, and food frequency questionnaires to characterize the diet of the mother.

Eligibility criteria:
inclusion criteria: * full-term babies whose mothers have no known medical conditions or complications during pregnancy. exclusion criteria: * preterm babies * babies whose mothers have significant medical conditions and/or significant complications during pregnancy.

Keywords: infant nutrition magnetic resonance spectroscopy infant brain development diffusion weighted imaging diffusion tensor tractography